You are here: Industry Insights > Market News > Granules gets US FDA nod for postpartum haemorrhage prevention drug

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Avatrombopag Maleate

BioHub® Magnetic Separator

Avatrombopag

Ursodeoxycholic acid

Troxerutin

CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

Granules gets US FDA nod for postpartum haemorrhage prevention drug

financialexpressMay 21, 2018

Tag: US , FDA , postpartum haemorrhage prevention drug

Favorites

Granules India said its subsidiary has received approval from the US health regulator for Methylergonovine tablets, used for the prevention and control of postpartum haemorrhage.

In a filing to BSE, Granules India said "the US Food and Drug Administration (US FDA) has approved its abbreviated new drug applications (ANDA) for Methylergonovine 0.2 mg tablets.

The ANDA was filed by Granules Pharmaceuticals Inc., a wholly-owned subsidiary of Granules India. The approved product is the bioequivalent to the reference listed drug product Methergine 0.2 mg, it added.

Register as Visitor to CPhI China 2018!

Previous:Morepen Laboratories posts 25% rise in its net profit in FY 2017-18

Next:Alembic Pharma posts net profit of Rs 93.79 cr in Q4

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Granules gets US FDA nod for postpartum haemorrhage prevention drug | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Chromstar® CL Resin for Size Exclusion Chromatography

60ml Wholesale custom logo 60ml horse vitamin pastes disposable syringe 60cc veterinary multi dose s

Acetic Acid,Glacial(99,9%)Ph.Eur./USP/JP parenteral grade

Betaxolol 98%min Pharmaceutical Vegetative nervous system drugs made in china

Tea Tree mushroom powder Agrocybe Cylindracea powder Agrocybe chaxingu powder Agrocybe aegirita powd

Continuous vacuum machine dryer for feed additive, animal feed &fatty acids

Copeinus Comatus Polysaccharides 30%

White Fungus Extract Powder

Coleus Forskohlii Extract Powder 20%

Maitake Mushroom Extract 10.0~30.0% Polysaccharides (UV)

Granules gets US FDA nod for postpartum haemorrhage prevention drug

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

You may likeMore>>

You may like
More>>